Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variant by Sophie Marbaix, Sophie Marbaix, Steven Simoens, Philippe Clevenbergh, Pascal Van Bleyenbergh, Keliane Liberman, Dimitri Dehenau

Subjects: “…cost-utility…”
Get full text

Matters arising: cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review by Carlo Lazzaro, Roberto Bergamaschi, Mauro Zaffaroni, Rocco Totaro, Damiano Paolicelli

Subjects: Get full text

Cost-utility and cost–benefit analysis of a multi-component intervention (NEXpro) for neck-related symptoms in Swiss office workers by Beatrice Brunner, Andrea Martina Aegerter, Venerina Johnston, Thomas Volken, Manja Deforth, Gisela Sjøgaard, Achim Elfering, Markus Melloh, the NEXpro Collaboration Group

Subjects: “…Cost-utility…”
Get full text

Cost-effectiveness of oral versus injectable disease modifying therapies in relapsing multiple sclerosis: a systematic review analysis by Mehdi Rezaee, Ramin Ravangard, Seyyed Morteza Mojtabaeian, Abdosaleh Jafari

Subjects: Get full text

SAĞLIK HİZMETLERİNDE EKONOMİK DEĞERLENDİRME TEKNİKLERİ ÜZERİNE BİR İNCELEME by Faruk Yılmaz, Özgür Aslan

Subjects: Get full text